Key Takeaways
- CDER is considering cancelling advisory committee meetings that were scheduled, but not formally announced, because support staff based in the drug and biologic centers have been laid off.
- The staff were responsible for meeting-specific tasks, including conflict-of-interest screening and travel arrangements, which raises questions about the agency's ability to conduct any adcomms in the near term.
- Numerous former FDA employees in other areas are getting requests to return temporarily to help ensure continuity of operations.
The US Food and Drug Administration is considering cancelling some advisory committee meetings in the wake of recent layoffs that have gutted the staff who plan and organize them.
Review staff and product sponsors are planning for advisory committee meetings, but the likelihood of most of those meetings actually happening given recent layoffs is increasingly unlikely.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?